ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL
-
Narrated by:
-
Written by:
About this listen
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What do the primary results from the EPCORE FL-1 trial tell us about epcoritamab + R2 vs R2 alone in patients with R/R FL?
In this interview, Falchi highlights that epcoritamab and R2 do not have overlapping toxicities and that the combination may offer synergistic activity. He concludes that epcoritamab sets a new benchmark as a readily available treatment for patients with R/R FL.
This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.